Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.

NCT06762431 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ENROLLING_BY_INVITATION

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukaemia (CLL)
Small Lymphocytic Lymphoma (SLL)

Interventions

DRUG: Lenalidomide
DRUG: Lenalidomide

Sponsor

Vitebsk Regional Clinical Cancer Centre

Collaborators

[object Object]